Lupin gets USFDA marketing nod for generic Welchol tablets

Lupin gets USFDA marketing nod for generic Welchol tablets

Medicine Tablets
Picture: Pixabay

Last Updated on December 20, 2020 by The Health Master

Pharma major Lupin Limited (Lupin) has received approval for its colesevelam hydrochloride tablets, 625 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Welchol tablets, 625 mg, of Daiichi Sankyo, Inc.

Colesevelam hydrochloride tablets, 625 mg, are indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia; to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Colesevelam hydrochloride tablets (RLD: Welchol) had an annual sales of approximately US$ 159 million in the US (IQVIA MAT September 2020).

Also read | Natco launches Anti Blood Clotting tablet in India

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.